Crinetics Pharmaceuticals Inc
General ticker "CRNX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $4.5B
Crinetics Pharmaceuticals Inc follows the US Stock Market performance with the rate: 63.8%.
Estimated limits based on current volatility of 2.8%: low 51.09$, high 54.01$
Factors to consider:
- Current price 16.0% above estimated high
- Earnings for 9 months up through Q3 are close to our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [22.75$, 46.50$]
- 2024-12-30 to 2025-12-30 estimated range: [21.47$, 44.00$]
Financial Metrics affecting the CRNX estimates:
- Negative: Non-GAAP EPS, $ of -3.70 <= 0.10
- Negative: Operating profit margin, % of -98.23 <= 1.03
- Negative: Operating cash flow per share per price, % of -7.82 <= 2.35
- Negative: negative Net income
- Positive: -3.48 < Investing cash flow per share, $ of -3.45
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term CRNX quotes
Long-term CRNX plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $1.08MM | $4.74MM | $4.01MM |
| Operating Expenses | $108.78MM | $172.62MM | $226.62MM |
| Operating Income | $-107.70MM | $-167.88MM | $-222.61MM |
| Non-Operating Income | $0.06MM | $3.96MM | $8.08MM |
| Interest Expense | $0.00MM | $4.32MM | $0.00MM |
| R&D Expense | $84.25MM | $130.22MM | $168.53MM |
| Income(Loss) | $-107.64MM | $-163.92MM | $-214.53MM |
| Taxes | $0.00MM | $-3.96MM | $0.00MM |
| Profit(Loss) | $-107.64MM | $-159.95MM | $-214.53MM |
| Stockholders Equity | $331.94MM | $316.33MM | $539.11MM |
| Inventory | $8.07MM | $0.00MM | $0.00MM |
| Assets | $351.01MM | $352.18MM | $635.35MM |
| Operating Cash Flow | $-88.59MM | $-115.20MM | $-166.31MM |
| Capital expenditure | $0.44MM | $1.66MM | $4.69MM |
| Investing Cash Flow | $-56.48MM | $-173.98MM | $-200.41MM |
| Financing Cash Flow | $252.68MM | $121.96MM | $388.94MM |
| Earnings Per Share* | $-2.78 | $-3.08 | $-3.69 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.